FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.

Previous post Levi Strauss slashes guidance as wholesale revenue drops
Next post Levi Strauss slashes guidance as wholesale revenue drops